Alkermes (NASDAQ:ALKS) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.

ALKS has been the topic of a number of other research reports. Credit Suisse Group set a $66.00 price target on Alkermes and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Barclays lowered Alkermes from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. J P Morgan Chase & Co set a $78.00 price target on Alkermes and gave the stock a “buy” rating in a research report on Friday, October 27th. UBS set a $54.00 price target on Alkermes and gave the stock a “hold” rating in a research report on Friday, October 27th. Finally, Mizuho set a $81.00 price objective on Alkermes and gave the stock a “buy” rating in a report on Saturday, October 21st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $63.55.

Alkermes (NASDAQ ALKS) traded up $1.41 during midday trading on Friday, hitting $53.70. The stock had a trading volume of 1,686,908 shares, compared to its average volume of 902,468. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes has a 52 week low of $46.42 and a 52 week high of $63.40.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.04. The company had revenue of $217.40 million for the quarter, compared to analyst estimates of $231.29 million. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. Alkermes’s revenue was up 20.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.09) earnings per share. research analysts anticipate that Alkermes will post -0.59 earnings per share for the current fiscal year.

In related news, SVP Michael J. Landine sold 15,000 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $48.71, for a total transaction of $730,650.00. Following the completion of the transaction, the senior vice president now directly owns 178,693 shares in the company, valued at $8,704,136.03. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard F. Pops sold 50,000 shares of the stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 122,930 shares of company stock valued at $6,051,110. 5.34% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Toronto Dominion Bank grew its stake in Alkermes by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after purchasing an additional 212 shares in the last quarter. Quantbot Technologies LP bought a new position in Alkermes in the third quarter valued at approximately $126,000. Virtu Financial LLC bought a new position in Alkermes in the third quarter valued at approximately $201,000. Dynamic Technology Lab Private Ltd bought a new position in Alkermes in the third quarter valued at approximately $214,000. Finally, Trexquant Investment LP bought a new position in Alkermes in the third quarter valued at approximately $218,000. Hedge funds and other institutional investors own 99.75% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Alkermes (ALKS) Lifted to “Hold” at ValuEngine” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/03/alkermes-alks-lifted-to-hold-at-valuengine.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.